Seres Therapeutics


Clinical-stage biotechnology company focused on development of rationally selected live bacterial consortia as therapeutic medicines. Activities include discovery and development of microbiome-targeted therapeutics, clinical development across infectious and immune/inflammatory indications, manufacturing and CMC process development for live biotherapeutics, regulatory submissions and commercialization experience.

Industries

Biopharma
Biotechnology
Health Care
Therapeutics
Biotech & Pharmaceuticals
Pharmaceutical and biotechnology
Biotechnology Research

Nr. of Employees

medium (51-250)

Seres Therapeutics


Patents

Compositions and methods

US-12605415-B2

View Details

Synergistic bacterial compositions and methods of production and use thereof

US-12409197-B2

View Details

Compositions and methods for treating antibiotic resistance

US-12214002-B2

View Details

Synergistic bacterial compositions and methods of production and use thereof

US-12083151-B2

View Details

Synergistic bacterial compositions and methods of production and use thereof

US-11918612-B2

View Details

Compositions and methods for treating cholestatic disease

US-11701394-B2

View Details
View All Patents

Products

Oral live biotherapeutic for prevention of recurrent Clostridioides difficile infection (commercialized; rights divested)

An approved oral spore-based live biotherapeutic developed to reduce recurrence of C. difficile infection in adults; later divested to a third party.


Services

Policy and program to provide investigational live biotherapeutic access under defined criteria.

Research collaborations with academic centers and non-profits to define microbiome signatures, enable patient access and advance development of live biotherapeutics.

Expertise Areas

  • Microbiome therapeutics development
  • Clinical trial management for infectious and immune-mediated indications
  • Bioprocessing and CMC for live biotherapeutics
  • Regulatory strategy and BLA submissions
  • Show More (3)

Key Technologies

  • Live bacterial consortium therapeutics
  • Microbial genomics and metagenomics
  • Bioinformatics and computational biology
  • Upstream and downstream bioprocessing
  • Show More (3)

News & Updates

Company led development and obtained FDA approval (April 2023) for an oral live biotherapeutic to prevent recurrence of C. difficile infection in adults.

Sale of commercial rights for the approved oral live biotherapeutic to a third party; transaction completed September 30, 2024.

Phase 1b placebo-controlled study (NCT04995653) in allo-HSCT patients reported reductions in bacterial bloodstream infections, systemic antibiotic exposure, and febrile neutropenia through day 100 compared to placebo.

Investigational program received Breakthrough Therapy designation and Fast Track designation for specific indications related to reducing bloodstream infections and graft-versus-host disease risk in allo-HSCT patients.


Similar organizations

Browse all ORGANIZATIONS

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.